Citadel Advisors
LABU icon

Citadel Advisors’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Citadel Advisors’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31M Buy
186,800
+22,235
+14% +$3.65M 0.01% 1832
2025
Q4 		$26.2M Sell
164,565
-52,465
-24% -$7.2M ﹤0.01% 2052
2025
Q3 		$20.3M Buy
217,030
+95,365
+78% +$6.74M ﹤0.01% 2316
2025
Q2 		$6.92M Sell
121,665
-113,095
-48% -$6M ﹤0.01% 3566
2025
Q1 		$14.3M Sell
234,760
-19,670
-8% -$1.68M ﹤0.01% 2418
2024
Q4 		$22.9M Buy
254,430
+23,390
+10% +$2.75M ﹤0.01% 2031
2024
Q3 		$29.7M Buy
231,040
+57,400
+33% +$7.49M 0.01% 1690
2024
Q2 		$19.7M Sell
173,640
-73,500
-30% -$7.87M ﹤0.01% 2015
2024
Q1 		$32.8M Buy
247,140
+6,360
+3% +$830K 0.01% 1573
2023
Q4 		$29.4M Buy
240,780
+138,560
+136% +$10.6M 0.01% 1642
2023
Q3 		$7.79M Buy
102,220
+6,280
+7% +$644K ﹤0.01% 3005
2023
Q2 		$11.4M Sell
95,940
-4,485
-4% -$559K ﹤0.01% 2512
2023
Q1 		$9.86M Buy
100,425
+56,535
+129% +$7.67M ﹤0.01% 2838
2022
Q4 		$6.21M Buy
43,890
+12,525
+40% +$1.75M ﹤0.01% 3515
2022
Q3 		$4.4M Sell
31,365
-9,870
-24% -$1.81M ﹤0.01% 4088
2022
Q2 		$5.56M Sell
41,235
-8,460
-17% -$1.44M ﹤0.01% 3602
2022
Q1 		$15.6M Buy
49,695
+20,050
+68% +$7.56M ﹤0.01% 2306
2021
Q4 		$21.3M Buy
29,645
+8,055
+37% +$7.71M ﹤0.01% 1937
2021
Q3 		$23.9M Buy
21,590
+4,510
+26% +$5.54M 0.01% 1805
2021
Q2 		$25.2M Buy
17,080
+4,190
+33% +$5.81M 0.01% 1811
2021
Q1 		$20.3M Buy
12,890
+3,965
+44% +$9.29M 0.01% 1940
2020
Q4 		$17.9M Sell
8,925
-120
-1% -$191K ﹤0.01% 1923
2020
Q3 		$9.69M Sell
9,045
-400
-4% -$459K ﹤0.01% 2325
2020
Q2 		$11.2M Sell
9,445
-2,480
-21% -$2.15M ﹤0.01% 2087
2020
Q1 		$5.38M Buy
11,925
+1,850
+18% +$1.68M ﹤0.01% 2609
2019
Q4 		$11.6M Sell
10,075
-575
-5% -$516K 0.01% 2050
2019
Q3 		$6.58M Buy
10,650
+4,880
+85% +$4.05M ﹤0.01% 2739
2019
Q2 		$5.79M Sell
5,770
-2,665
-32% -$2.58M ﹤0.01% 2889
2019
Q1 		$10.1M Buy
8,435
+2,000
+31% +$2.08M 0.01% 2061
2018
Q4 		$4.23M Buy
6,435
+2,785
+76% +$2.92M ﹤0.01% 3023
2018
Q3 		$6.79M Sell
3,650
-530
-13% -$1.04M ﹤0.01% 2597
2018
Q2 		$7.94M Buy
4,180
+100
+2% +$176K ﹤0.01% 2185
2018
Q1 		$6.48M Buy
4,080
+1,020
+33% +$1.9M ﹤0.01% 2172
2017
Q4 		$4.76M Sell
3,060
-25
-0.8% -$38.3K ﹤0.01% 2530
2017
Q3 		$5.27M Buy
3,085
+615
+25% +$853K ﹤0.01% 2259
2017
Q2 		$3.12M Buy
2,470
+825
+50% +$832K ﹤0.01% 2616
2017
Q1 		$1.57M Buy
1,645
+215
+15% +$192K ﹤0.01% 3372
2016
Q4 		$895K Sell
1,430
-305
-18% -$229K ﹤0.01% 4013
2016
Q3 		$1.69M Buy
+1,735
New +$1.43M ﹤0.01% 3176

Other funds holding LABU

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citadel Advisors's LABU Position: Q4 2025 in Review

Citadel Advisors sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q4 2025, closing a stake of 91,850 shares — an estimated $12.6M sold.

Citadel Advisors first reported a position in LABU in Q4 2015 and held it in 33 quarters. The position peaked at $14.4M in Q4 2022. 40 funds tracked by Wall St. Rank hold LABU as of Q4 2025.

  • Citadel Advisors reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 91,850 Direxion Daily S&P Biotech Bull 3X ETF shares in Q4 2025, an estimated $12.6M.
  • Citadel Advisors first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q4 2015 and held it in 33 quarters.
  • Citadel Advisors's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $14.4M in Q4 2022.
  • 40 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.